# Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

> **NCT04248595** · PHASE2 · UNKNOWN · sponsor: **Ge Zheng** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Homoharringtonine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04248595
- **Lead sponsor:** Ge Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248595, "Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04248595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*